-
J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
•
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global sales of USD 63.7 billion for the first nine months of the year. This marks a 7.5% year-on-year (YOY) expansion in operational terms, reflecting robust performance across both of the company’s main business segments. Segment…
-
Huadong Medicine Secures Global Licensing Agreement for ATGC-110 Botulinum Toxin A Injection
•
China-based Huadong Medicine Co., Ltd. (SHE: 000963) has announced a strategic licensing agreement with South Korea’s ATGC, granting Huadong exclusive global rights (excluding India) to ATGC’s botulinum toxin A injection, ATGC-110. The agreement also provides a non-exclusive license for South Korea, encompassing clinical development, regulatory filing, and commercialization rights across…
-
Apeloa Pharmaceutical Enters Ten-Year Partnership with Wuhan Hesheng Technology
•
China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) has announced a significant ten-year partnership agreement with Wuhan Hesheng Technology Co., Ltd. While the financial specifics of the deal remain undisclosed, the collaboration is poised to enhance both companies’ capabilities in the pharmaceutical sector. Collaboration Focused…
-
BeiGene Submits Supplementary BLA for Tislelizumab in Small Cell Lung Cancer
•
BeiGene (NASDAQ: BGNE) has announced that its supplementary Biologic License Application (sBLA) for the programmed death-1 (PD-1) inhibitor tislelizumab has been accepted for review by the Center for Drug Evaluation (CDE) in China. The application seeks approval for the drug to be used in combination with etoposide and chemotherapy as…
-
Mabwell to Present Promising Clinical Data at 2023 ESMO Congress
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the latest clinical data for its investigational drugs 9MW2821 and 8MW0511 at the upcoming 2023 European Society for Medical Oncology (ESMO) Congress. This presentation underscores the company’s commitment to advancing innovative therapies in oncology. 9MW2821: Promising…
-
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
•
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led…
-
SciClone Pharmaceuticals Partners with Shanghai Pharmaceutical and Menarini Group
•
China’s SciClone Pharmaceuticals Inc. (HKG: 6600) has entered into a collaborative agreement with Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) and Italy-headquartered Menarini Group. While specific details of the partnership remain undisclosed, this alliance marks a significant step for all parties involved. Focus on Oncology and Infectious Diseases SciClone is dedicated…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
